News

BioMarin Receives FDA’s Rare Pediatric Disease Designation For Drisapersen To Address Duchenne Muscular Dystrophy

BioMarin Pharmaceutical Inc. has recently announced that the United States Food and Drug Administration (FDA) attributed a rare pediatric disease designation for drisapersen, a potential treatment for individuals suffering with Duchenne Muscular Dystrophy (DMD) who are responsive to exon 51 skipping treatment. Drisapersen has been previously granted Orphan Drug and Fast…

Report Highlights Innovative And Diverse Pipeline Of Products For Treating Duchenne And Becker Muscular Dystrophies

A new 77-page GBI Research report entitled “Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy – Identifying and Commercializing First-in-Class Innovation” identifies and highlights a highly innovative and diverse pipeline of products for treating Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) Currently in the pipeline are 84…

Special RNA Molecules Important in Muscular Dystrophy

Messenger RNA (mRNA) and DNA are commonly thought of as the workhorse nucleic acids of a cell. Specialized proteins within a cell transcribe DNA strands into mRNA strands, which are then translated into proteins. Within a cell, there exist other types of nucleic acids that play important roles in maintaining…

Traditional Chinese Medicine Used to Help DMD Patients in Study

While groundbreaking discoveries rooted in the laboratory are making progress in treating children with Duchenne muscular dystrophy (DMD), acupuncture and Traditional Chinese Medicine (TCM) also hold potential to help alleviate symptoms and enhance muscle function. A team of researchers combined a number of alternative therapies along with drug therapy to…